1. Home
  2. Analysis
  3. Paroxetine
  4. Ubrelvy

Paroxetine and Ubrelvy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Paroxetine (paroxetine hydrochloride) and Ubrelvy (ubrogepant). Common drug interactions include dermatitis atopic among females.

The phase IV clinical study analyzes what interactions people have when they take Paroxetine and Ubrelvy. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Paroxetine?

Paroxetine has active ingredients of paroxetine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 65,088 Paroxetine users. Check the latest studies of Paroxetine.

What is Ubrelvy?

Ubrelvy has active ingredients of ubrogepant. eHealthMe is studying from 3,585 Ubrelvy users. Check the latest studies of Ubrelvy.

On Jul, 09, 2026

11 people who take Paroxetine and Ubrelvy together, and have interactions are studied.

Paroxetine and Ubrelvy drug interactions.

What are the common drug interactions of Paroxetine and Ubrelvy, by gender? *:

female:

  1. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  2. Asthma
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Pruritus (severe itching of the skin)
  5. Rash
  6. Sleep disorder
  7. Urticaria (rash of round, red welts on the skin that itch intensely)
  8. Chest pain
  9. Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
  10. Discomfort

male:

n/a

What are the common drug interactions of Paroxetine and Ubrelvy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Asthma
  2. Dry eye (lack of adequate tears)
  3. Glucose tolerance impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis)
  4. Neuropathy peripheral (surface nerve damage)
  5. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  6. Pruritus (severe itching of the skin)
  7. Urticaria (rash of round, red welts on the skin that itch intensely)

60+:

n/a

What are the existing conditions these people have? *

  1. Migraine (headache): 3 people, 27.27%
  2. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 27.27%
  3. Asthma: 2 people, 18.18%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 9.09%
  5. Nasal Polyps (masses that develop in the lining of the nose): 1 person, 9.09%
  6. Headache (pain in head): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Paroxetine and Ubrelvy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Paroxetine and Ubrelvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Paroxetine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ubrelvy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Paroxetine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ubrelvy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on paroxetine hydrochloride and ubrogepant (the active ingredients of Paroxetine and Ubrelvy, respectively), and Paroxetine and Ubrelvy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.